Compare MCFT & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCFT | MRVI |
|---|---|---|
| Founded | 1968 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.9M | 449.6M |
| IPO Year | 2015 | 2020 |
| Metric | MCFT | MRVI |
|---|---|---|
| Price | $18.44 | $3.61 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $22.20 | $4.58 |
| AVG Volume (30 Days) | 135.9K | ★ 1.3M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $287,846,000.00 | $192,435,000.00 |
| Revenue This Year | $9.21 | N/A |
| Revenue Next Year | $8.78 | $9.04 |
| P/E Ratio | $19.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.39 | $1.67 |
| 52 Week High | $23.94 | $6.21 |
| Indicator | MCFT | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 56.78 |
| Support Level | $18.07 | $3.32 |
| Resistance Level | $18.76 | $3.76 |
| Average True Range (ATR) | 0.62 | 0.20 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 69.71 | 68.04 |
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.